 |
Top 14 Kidney Disease treatment startups in USA
Oct 25, 2025 | By Jason Kwon | 34 |
1
Funding: $185.2M
Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development.
Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development.
2
Funding: $624M
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
3
Funding: $555.1M
Monogram Health is a nephrologists to deliver transformative kidney care services.
Monogram Health is a nephrologists to deliver transformative kidney care services.
4
Funding: $496M
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
5
Funding: $442.5M
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
6
Funding: $386M
Strive Health is a provider of care delivery models aimed at improving chronic kidney disease care.
Strive Health is a provider of care delivery models aimed at improving chronic kidney disease care.
7
Funding: $266M
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
8
Funding: $198.8M
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
9
Funding: $125.4M
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
10
Funding: $100M
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.
11
Funding: $77.2M
AWAK develops wearable dialysis machines that operate and function like a normal kidney, for continuous dialysis.
AWAK develops wearable dialysis machines that operate and function like a normal kidney, for continuous dialysis.
12
Funding: $51M
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
13
Funding: $7.1M
Early is Good (EIG) is leading the way in early detection and diagnosis of renal disease. With its innovative approach of assessing specific biomarkers found in urine, EIG is empowering patients and healthcare providers with the tools they need to detect and treat renal diseases such as bladder, kidney, and prostate cancer at an early stage. With the support of Social Capital, a Silicon Valley-based technology investment firm, EIG is well positioned to revolutionize the diagnostic industry and bring hope to millions of patients around the world.
Early is Good (EIG) is leading the way in early detection and diagnosis of renal disease. With its innovative approach of assessing specific biomarkers found in urine, EIG is empowering patients and healthcare providers with the tools they need to detect and treat renal diseases such as bladder, kidney, and prostate cancer at an early stage. With the support of Social Capital, a Silicon Valley-based technology investment firm, EIG is well positioned to revolutionize the diagnostic industry and bring hope to millions of patients around the world.
14
NuVascular Technologies, Inc. is developing the next-generation of medical devices that will specifically treat patients suffering from end-stage renal (kidney) disease with the goal of helping patients live better and longer lives.
★
See also:
